Victoza vs Saxenda
Same Drug (Liraglutide), Different Dose and Purpose (2026)
Here's the key fact most people miss: Victoza and Saxenda are the same molecule — liraglutide. The difference is dose and indication. Victoza (up to 1.8 mg) is approved for type 2 diabetes; Saxenda (up to 3.0 mg) is approved for weight loss. Both are daily injections from Novo Nordisk.
Victoza vs Saxenda: At a Glance
- ✓Liraglutide — GLP-1 receptor agonist
- ✓Once-daily subcutaneous injection
- ✓Max dose 1.8 mg
- ✓FDA-approved for type 2 diabetes
- ✓Lowers HbA1c; modest weight loss
- ✓Novo Nordisk
- ✓Liraglutide — same GLP-1 molecule
- ✓Once-daily subcutaneous injection
- ✓Max dose 3.0 mg
- ✓FDA-approved for weight management (obesity)
- ✓SCALE: ~8% mean weight loss
- ✓Novo Nordisk
Detailed Comparison
| Feature | Victoza | Saxenda |
|---|---|---|
| Generic | Liraglutide | Liraglutide (same drug)Best |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Max Dose | 1.8 mg daily | 3.0 mg daily |
| Indication | Type 2 diabetes | Obesity / weight management |
| Administration | Once-daily injection | Once-daily injection |
| Primary Goal | Blood sugar control | Weight loss |
| Weight Loss | Modest (secondary effect) | ~8% (SCALE trial) |
| Mechanism | GLP-1 agonist | GLP-1 agonist |
| Side Effects | Nausea, diarrhea | Nausea, vomiting, diarrhea |
| Pen | Lower-dose pen | Higher-dose pen |
Which One Do You Need?
Goal: Diabetes
Victoza (1.8 mg) is the on-label liraglutide for type 2 diabetes, with established HbA1c and cardiovascular data.
Goal: Weight Loss
Saxenda (3.0 mg) is the on-label liraglutide for obesity — same drug, higher dose, approved specifically for weight management.
Same Side Effects
Because it's the same molecule, the side-effect profile is similar; the higher Saxenda dose can mean more GI symptoms.
Daily, Not Weekly
Both are once-daily injections — more frequent than weekly drugs like Ozempic, Wegovy, or Zepbound.
Newer Options Exist
Liraglutide is older; weekly semaglutide and tirzepatide generally produce more weight loss than Saxenda.
Coverage
Indication drives insurance: diabetes plans cover Victoza, weight-management benefits (where they exist) cover Saxenda.
The Bottom Line
Victoza and Saxenda are not really competitors — they are the same drug (liraglutide) at two different doses for two different jobs. Victoza tops out at 1.8 mg and is approved for type 2 diabetes. Saxenda goes up to 3.0 mg and is approved for weight loss. You generally use the one that matches your diagnosis and goal.
Because it is the same molecule, the experience is similar, with the higher Saxenda dose tending to cause a bit more nausea during titration. Both are once-daily injections — a higher commitment than the weekly drugs.
If weight loss is your goal, it is worth knowing that liraglutide is the older, less potent option: Saxenda's roughly 8% weight loss is below what weekly semaglutide (Wegovy) or tirzepatide (Zepbound) achieve. Whichever you take, track your dose, weight, and glucose in Shotlee.
Victoza vs Saxenda: Frequently Asked Questions
Yes — both are liraglutide. The difference is dose and indication: Victoza maxes at 1.8 mg and is approved for type 2 diabetes; Saxenda goes to 3.0 mg and is approved for weight loss. Both are daily injections from Novo Nordisk.
Victoza causes some weight loss as a secondary effect, but it is approved for diabetes, not obesity, and tops out at a lower dose. Saxenda is the liraglutide product approved and dosed for weight management.
Saxenda — its higher 3.0 mg dose produced about 8% mean weight loss in the SCALE trial. Victoza's lower diabetes dose produces less weight loss.
They're similar because it's the same molecule, but the higher Saxenda dose can cause more gastrointestinal side effects (nausea, vomiting) during titration.
Yes. Shotlee tracks liraglutide at any dose, plus weight, glucose, and side effects — useful whether you're on the diabetes or weight-loss version.
Track Victoza or Saxenda in Shotlee
Free dose logging, weight, glucose, and side-effect tracking for liraglutide at any dose.
📚References & sources
Latest on Victoza
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
FDA's GLP-1 Compounding Crackdown: What Patients Need to Know
The U.S. Food and Drug Administration (FDA) has announced a significant proposal to restrict the compounding of popular GLP-1 medications, including semaglutide and tirzepatide. This move aims to enhance patient safety and uphold the integrity of approved drug products. Here's a comprehensive look at what this means for individuals managing weight and diabetes.
7 min read
Ozempic Users Warned: Don't Skip Exercise, Study Urges
Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.
5 min read